1、Janssen AG, Mansour K, Bos J, et al. Diameter of the bony lacrimal
canal: normal values and values related to nasolacrimal duct
obstruction: assessment with CT[ J]. AJNR Am J Neuroradiol, 2001,
22(5): 845-850.Janssen AG, Mansour K, Bos J, et al. Diameter of the bony lacrimal
canal: normal values and values related to nasolacrimal duct
obstruction: assessment with CT[ J]. AJNR Am J Neuroradiol, 2001,
22(5): 845-850.
2、Chin J, Lam V, Chan R, et al. Comparative study of stenting and ostium
packing in endoscopic dacryocystorhinostomy for primary acquired
nasolacrimal duct obstruction[ J]. Sci Rep, 2020, 10(1): 46.Chin J, Lam V, Chan R, et al. Comparative study of stenting and ostium
packing in endoscopic dacryocystorhinostomy for primary acquired
nasolacrimal duct obstruction[ J]. Sci Rep, 2020, 10(1): 46.
3、Yuksel D, Kosker M, Akoz I, et al. Long-term results of simultaneous
bilateral external dacryocystorhinostomy in cases with bilateral
dacryostenosis[ J]. Semin Ophthalmol, 2015, 30(1): 20-24.Yuksel D, Kosker M, Akoz I, et al. Long-term results of simultaneous
bilateral external dacryocystorhinostomy in cases with bilateral
dacryostenosis[ J]. Semin Ophthalmol, 2015, 30(1): 20-24.
4、Woog J. The incidence of symptomatic acquired lacrimal outflow
obstruction among residents of Olmsted County, Minnesota, 1976-
2000 (an American Ophthalmological Society thesis)[ J]. Trans Am
Ophthalmol Soc, 2007, 105: 649-666.Woog J. The incidence of symptomatic acquired lacrimal outflow
obstruction among residents of Olmsted County, Minnesota, 1976-
2000 (an American Ophthalmological Society thesis)[ J]. Trans Am
Ophthalmol Soc, 2007, 105: 649-666.
5、Ali MJ, Paulsen F. Etiopathogenesis of primary acquired nasolacrimal
duct obstruction: what we know and what we need to know[ J].
Ophthalmic Plast Reconstr Surg, 2019, 35(5): 426-433.Ali MJ, Paulsen F. Etiopathogenesis of primary acquired nasolacrimal
duct obstruction: what we know and what we need to know[ J].
Ophthalmic Plast Reconstr Surg, 2019, 35(5): 426-433.
6、Ali MJ, Paulsen F. Prolactin and prolactin-inducible protein (PIP) in
the pathogenesis of primary acquired nasolacrimal duct obstruction
(PANDO)[ J]. Med Hypotheses, 2019, 125: 137-138.Ali MJ, Paulsen F. Prolactin and prolactin-inducible protein (PIP) in
the pathogenesis of primary acquired nasolacrimal duct obstruction
(PANDO)[ J]. Med Hypotheses, 2019, 125: 137-138.
7、Yan%C4%B1k%20%C3%96%2C%20Ho%C5%9Fal%20B%2C%20Tekeli%20A%2C%20et%20al.%20Viral%20nucleic%20acid%20analysis%20with%20PCR%20in%20%0Alacrimal%20tissue%20and%20nasal%20swab%20samples%20of%20primary%20acquired%20nasolacrimal%20%0Aduct%20obstruction%20cases%5BJ%5D.%20Eur%20J%20Ophthalmol%2C%202021%2C%2031(1)%3A%20138-143.Yan%C4%B1k%20%C3%96%2C%20Ho%C5%9Fal%20B%2C%20Tekeli%20A%2C%20et%20al.%20Viral%20nucleic%20acid%20analysis%20with%20PCR%20in%20%0Alacrimal%20tissue%20and%20nasal%20swab%20samples%20of%20primary%20acquired%20nasolacrimal%20%0Aduct%20obstruction%20cases%5BJ%5D.%20Eur%20J%20Ophthalmol%2C%202021%2C%2031(1)%3A%20138-143.
8、Lee-Wing MW, Ashenhurst M. Clinicopathologic analysis of 166
patients with primary acquired nasolacrimal duct obstruction[ J].
Ophthalmology, 2001, 108(11): 2038-2040.Lee-Wing MW, Ashenhurst M. Clinicopathologic analysis of 166
patients with primary acquired nasolacrimal duct obstruction[ J].
Ophthalmology, 2001, 108(11): 2038-2040.
9、Linberg JV, McCormick S. Primary acquired nasolacrimal duct
obstruction. A clinicopathologic report and biopsy technique[ J].
Ophthalmology, 1986, 93(8): 1055-1063.Linberg JV, McCormick S. Primary acquired nasolacrimal duct
obstruction. A clinicopathologic report and biopsy technique[ J].
Ophthalmology, 1986, 93(8): 1055-1063.
10、Paulsen FP, Thale A , Maune S, et al. New insights into the
pathophysiology of primary acquired dacryostenosis[ J]. Ophthalmology,
2001, 108(12): 2329-2336.Paulsen FP, Thale A , Maune S, et al. New insights into the
pathophysiology of primary acquired dacryostenosis[ J]. Ophthalmology,
2001, 108(12): 2329-2336.
11、Mauriello JA, Palydowycz S, DeLuca J. Clinicopathologic study of
lacrimal sac and nasal mucosa in 44 patients with complete acquired
nasolacrimal duct obstruction[ J]. Ophthalmic Plast Reconstr Surg,
1992, 8(1): 13-21.
Mauriello JA, Palydowycz S, DeLuca J. Clinicopathologic study of
lacrimal sac and nasal mucosa in 44 patients with complete acquired
nasolacrimal duct obstruction[ J]. Ophthalmic Plast Reconstr Surg,
1992, 8(1): 13-21.
12、Das AV, Rath S, Naik M, et al. The incidence of lacrimal drainage
disorders across a tertiary eye care network: customization of
an indigenously developed electronic medical record system—
eyeSmart[ J]. Ophthalmic Plast Reconstr Surg, 2019, 35(4): 354-356.Das AV, Rath S, Naik M, et al. The incidence of lacrimal drainage
disorders across a tertiary eye care network: customization of
an indigenously developed electronic medical record system—
eyeSmart[ J]. Ophthalmic Plast Reconstr Surg, 2019, 35(4): 354-356.
13、Ramey NA, Hoang J, Richard M. Multidetector CT of nasolacrimal
canal morphology: normal variation by age, gender, and race[ J].
Ophthalmic Plast Reconstr Surg, 2013, 29(6): 475-480.Ramey NA, Hoang J, Richard M. Multidetector CT of nasolacrimal
canal morphology: normal variation by age, gender, and race[ J].
Ophthalmic Plast Reconstr Surg, 2013, 29(6): 475-480.
14、倪长宝, 李惠民, 李崇谦, 等. 国人成人鼻泪管的解剖学测量[ J].
临床耳鼻咽喉科杂志, 1999, 13(2): 62-63.
NI CB, LI HM, LI CQ, et al. The applied
anatomy and measure of nasolacrimal duct[ J]. Journal of Clinical
Otorhinolaryngology, 1999, 13(2): 62-63.倪长宝, 李惠民, 李崇谦, 等. 国人成人鼻泪管的解剖学测量[ J].
临床耳鼻咽喉科杂志, 1999, 13(2): 62-63.
NI CB, LI HM, LI CQ, et al. The applied
anatomy and measure of nasolacrimal duct[ J]. Journal of Clinical
Otorhinolaryngology, 1999, 13(2): 62-63.
15、Dikici O, Uluta HG. Relationship between primar y acquired
nasolacrimal duct obstruction, paranasal abnormalities and nasal septal
deviation[ J]. J Craniofac Surg, 2020, 31(3): 782-786.Dikici O, Uluta HG. Relationship between primar y acquired
nasolacrimal duct obstruction, paranasal abnormalities and nasal septal
deviation[ J]. J Craniofac Surg, 2020, 31(3): 782-786.
16、Avasthi P, Misra R, Sood A. Clinical and anatomical considerations of
dacryocystitis[ J]. Int Surg, 1971, 55(3): 200-203.Avasthi P, Misra R, Sood A. Clinical and anatomical considerations of
dacryocystitis[ J]. Int Surg, 1971, 55(3): 200-203.
17、Estes JL, Tsiouris A, Christos P, et al. Three-dimensional volumetric
assessment of the nasolacrimal duct in patients with obstruction[ J].
Ophthalmic Plast Reconstr Surg, 2015, 31(3): 211-214.Estes JL, Tsiouris A, Christos P, et al. Three-dimensional volumetric
assessment of the nasolacrimal duct in patients with obstruction[ J].
Ophthalmic Plast Reconstr Surg, 2015, 31(3): 211-214.
18、Owji N, Radaei M, Khademi B. The relationship between primary
acquired nasolacrimal duct obstruction and gastroesophageal reflux[ J].
Curr Eye Res, 2018, 43(10): 1239-1243.Owji N, Radaei M, Khademi B. The relationship between primary
acquired nasolacrimal duct obstruction and gastroesophageal reflux[ J].
Curr Eye Res, 2018, 43(10): 1239-1243.
19、Mehta%20S%2C%20Ying%20G%2C%20Hussain%20A%2C%20et%20al.%20Is%20gastroesophageal%20reflux%20disease%20%0Aassociated%20with%20primary%20acquired%20nasolacrimal%20duct%20obstruction%3F%5B%20J%5D.%20%0AOrbit%2C%202018%2C%2037(2)%3A%20135-139.Mehta%20S%2C%20Ying%20G%2C%20Hussain%20A%2C%20et%20al.%20Is%20gastroesophageal%20reflux%20disease%20%0Aassociated%20with%20primary%20acquired%20nasolacrimal%20duct%20obstruction%3F%5B%20J%5D.%20%0AOrbit%2C%202018%2C%2037(2)%3A%20135-139.
20、Watanabe A, Kondoh E, Selva D, et al. Relationship between frequent
swimming pool use and lacrimal duct obstruction[ J]. Acta Ophthalmol,
2014, 92(3): e242-e243.Watanabe A, Kondoh E, Selva D, et al. Relationship between frequent
swimming pool use and lacrimal duct obstruction[ J]. Acta Ophthalmol,
2014, 92(3): e242-e243.
21、Kashkouli M, Rezaee R, Nilforoushan N, et al. Topical antiglaucoma
medications and lacrimal drainage system obstruction[ J]. Ophthalmic
Plast Reconstr Surg, 2008, 24(3): 172-175.Kashkouli M, Rezaee R, Nilforoushan N, et al. Topical antiglaucoma
medications and lacrimal drainage system obstruction[ J]. Ophthalmic
Plast Reconstr Surg, 2008, 24(3): 172-175.
22、Seider N, Miller B, Beiran I. Topical glaucoma therapy as a risk factor
for nasolacrimal duct obstruction[ J]. Am J Ophthalmol, 2008, 145(1):
120-123.Seider N, Miller B, Beiran I. Topical glaucoma therapy as a risk factor
for nasolacrimal duct obstruction[ J]. Am J Ophthalmol, 2008, 145(1):
120-123.
23、Zolli CL, Shannon G. Dacryocystorhinostomy: a review of 119
cases[ J]. Ophthalmic Surg, 1982, 13(11): 905-910.Zolli CL, Shannon G. Dacryocystorhinostomy: a review of 119
cases[ J]. Ophthalmic Surg, 1982, 13(11): 905-910.
24、Kashkouli MB, Sadeghipour A, Kaghazkanani R, et al. Pathogenesis of
primary acquired nasolacrimal duct obstruction[ J]. Orbit, 2010, 29(1):
11-15.Kashkouli MB, Sadeghipour A, Kaghazkanani R, et al. Pathogenesis of
primary acquired nasolacrimal duct obstruction[ J]. Orbit, 2010, 29(1):
11-15.
25、Gupta A, Prabhakaran V, Dodd T, et al. Characterization of lacrimal sac
histology: an immunohistochemical study[ J]. Clin Exp Ophthalmol,
2012, 40(9): 869-873.Gupta A, Prabhakaran V, Dodd T, et al. Characterization of lacrimal sac
histology: an immunohistochemical study[ J]. Clin Exp Ophthalmol,
2012, 40(9): 869-873.
26、Ali MJ, Schicht M, Paulsen F. Qualitative hormonal profiling of the
lacrimal drainage system: potential insights into the etiopathogenesis of
primary acquired nasolacrimal duct obstruction[ J]. Ophthalmic Plast
Reconstr Surg, 2017, 33(5): 381-388.Ali MJ, Schicht M, Paulsen F. Qualitative hormonal profiling of the
lacrimal drainage system: potential insights into the etiopathogenesis of
primary acquired nasolacrimal duct obstruction[ J]. Ophthalmic Plast
Reconstr Surg, 2017, 33(5): 381-388.
27、Ali MJ, Venugopal A, Ranganath K, et al. Soluble glycoproteins of
the lacrimal sac: role in defense with special reference to prolactininducible protein (PIP)[ J]. Orbit, 2019, 38(4): 279-284.Ali MJ, Venugopal A, Ranganath K, et al. Soluble glycoproteins of
the lacrimal sac: role in defense with special reference to prolactininducible protein (PIP)[ J]. Orbit, 2019, 38(4): 279-284.
28、Nemet AY, Vinker S. Associated morbidity of nasolacrimal duct
obstruction—a large community based case-control study[ J]. Graefes
Arch Clin Exp Ophthalmol, 2014, 252(1): 125-130.Nemet AY, Vinker S. Associated morbidity of nasolacrimal duct
obstruction—a large community based case-control study[ J]. Graefes
Arch Clin Exp Ophthalmol, 2014, 252(1): 125-130.
29、Chung SY, Rafailov L, Turbin R, et al. The microbiologic profile of
dacryocystitis[ J]. Orbit, 2019, 38(1): 72-78.Chung SY, Rafailov L, Turbin R, et al. The microbiologic profile of
dacryocystitis[ J]. Orbit, 2019, 38(1): 72-78.
30、Mitra S, Chayani N, Mohapatra D, et al. High prevalence of biofilmforming mrsa in the conjunctival flora in chronic dacryocystitis[ J].
Semin Ophthalmol, 2019, 34(2): 74-79.Mitra S, Chayani N, Mohapatra D, et al. High prevalence of biofilmforming mrsa in the conjunctival flora in chronic dacryocystitis[ J].
Semin Ophthalmol, 2019, 34(2): 74-79.
31、Eshraghi B, Abdi P, Akbari M, et al. Microbiologic spectrum of acute
and chronic dacryocystitis[ J]. Int J Ophthalmol, 2014, 7(5): 864-867.Eshraghi B, Abdi P, Akbari M, et al. Microbiologic spectrum of acute
and chronic dacryocystitis[ J]. Int J Ophthalmol, 2014, 7(5): 864-867.
32、Lee JK, Kim TH. Changes in cytokines in tears after endoscopic
endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction[ J]. Eye (Lond), 2014, 28(5): 600-607.Lee JK, Kim TH. Changes in cytokines in tears after endoscopic
endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction[ J]. Eye (Lond), 2014, 28(5): 600-607.
33、Ali MJ, Patnaik S, Kelkar N, et al. Alteration of tear cytokine expressions
in primary acquired nasolacrimal duct obstruction - potential insights
into the etiopathogenesis[ J]. Curr Eye Res, 2020, 45(4): 435-439.Ali MJ, Patnaik S, Kelkar N, et al. Alteration of tear cytokine expressions
in primary acquired nasolacrimal duct obstruction - potential insights
into the etiopathogenesis[ J]. Curr Eye Res, 2020, 45(4): 435-439.
34、Pahuja NK, Shetty R, Deshmukh R, et al. In vivo confocal microscopy
and tear cytokine analysis in post-LASIK ectasia[ J]. Br J Ophthalmol,
2017, 101(12): 1604-1610.Pahuja NK, Shetty R, Deshmukh R, et al. In vivo confocal microscopy
and tear cytokine analysis in post-LASIK ectasia[ J]. Br J Ophthalmol,
2017, 101(12): 1604-1610.
35、Guyette N, Williams L, Tran MT, et al. Comparison of low-abundance
biomarker levels in capillary-collected nonstimulated tears and washout
tears of aqueous-deficient and normal patients[ J]. Invest Ophthalmol
Vis Sci, 2013, 54(5): 3729-3737.Guyette N, Williams L, Tran MT, et al. Comparison of low-abundance
biomarker levels in capillary-collected nonstimulated tears and washout
tears of aqueous-deficient and normal patients[ J]. Invest Ophthalmol
Vis Sci, 2013, 54(5): 3729-3737.
36、Carre%C3%B1o%20E%2C%20Portero%20A%2C%20Herreras%20JM%2C%20et%20al.%20Cytokine%20and%20chemokine%20%0Atear%20levels%20in%20patients%20with%20uveitis%5B%20J%5D.%20Acta%20Ophthalmol%2C%202017%2C%2095(5)%3A%20%0Ae405-e414.Carre%C3%B1o%20E%2C%20Portero%20A%2C%20Herreras%20JM%2C%20et%20al.%20Cytokine%20and%20chemokine%20%0Atear%20levels%20in%20patients%20with%20uveitis%5B%20J%5D.%20Acta%20Ophthalmol%2C%202017%2C%2095(5)%3A%20%0Ae405-e414.
37、Tong L, Wong TY, Cheng Y. Level of tear cytokines in population-level
participants and correlation with clinical features[ J]. Cytokine, 2018,
110: 452-458.Tong L, Wong TY, Cheng Y. Level of tear cytokines in population-level
participants and correlation with clinical features[ J]. Cytokine, 2018,
110: 452-458.
38、Carre%C3%B1o%20E%2C%20Enr%C3%ADquez-de-Salamanca%20A%2C%20Tes%C3%B3n%20M%2C%20et%20al.%20Cytokine%20and%20%0Achemokine%20levels%20in%20tears%20from%20healthy%20subjects%5B%20J%5D.%20Acta%20Ophthalmol%2C%20%0A2010%2C%2088(7)%3A%20e250-e258.Carre%C3%B1o%20E%2C%20Enr%C3%ADquez-de-Salamanca%20A%2C%20Tes%C3%B3n%20M%2C%20et%20al.%20Cytokine%20and%20%0Achemokine%20levels%20in%20tears%20from%20healthy%20subjects%5B%20J%5D.%20Acta%20Ophthalmol%2C%20%0A2010%2C%2088(7)%3A%20e250-e258.
